Abstract
Most protocols of gene therapy clinical trials are based on immunotherapy strategies with genetically modified tumor vaccines (GMTV). The major issue when designing GMTV is gene delivery system; RV proven to be very useful for ex vivo transduction of therapeutic genes. The advantages of RV include: easy manipulation of small viral genome, stable integration of transduced gene and safety. Most frequently, Gibbon Ape Leukemia Virus (GaLV) and Amphotropic Murine Leukemia Virus (AMuLV) envelope proteins are used to pseudotype RV-based vectors. Such vector pseudotypes infect target cells by their specific receptors: PiT1 and PiT2, respectively. Both receptors belong to the same family’, and despite high degree homology, no cross interference is observed.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
O’Hara B., Johann S.V., Klinger H.P., Blair D.G., Rubinson H., Dunn K.J., Sass P., Vitek S.M. and Robins T. (1990) Characterization of human gene confering sensitivity to infection by gibbon ape leukemia virus. Cell Growth Differ. 1, 119–127.
Bauer T.R. Jr., Miller A.D. and Hickstein D.D. (1995) Improved transfer of the leukocyte integrin CD18 subunit into hematopoietic cell lines by using retroviral vectors having gibbon ape leukemia virus envelope. Blood 86, 2379–2387.
Orlic D., Girard L.J., Jordan C.T., Anderson S.M., Cline A.P., and Bodin D.M. (1996) The level of mRNA encoding the amphotropic retrovirus receptor in mouse and human hematopoietic stem cells is low and correlates with the efficiency of retrovirus transduction. Proc. Natl. Acad. Sci. U.S.A., 93, 11097–11102.
Uckert W., Willimsky G., Pedresen F.S., Blankenstein T., and Pedersen L. (1998) RNA levels of human Retrovirus Receptors PiT1 and PiT2 do not correlate with infectibility by three retroviral vector pseudotypes. Human Gene Ther. 9:2619–2627.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Springer Science+Business Media New York
About this chapter
Cite this chapter
Grabarczyk, P., Gryska, K., Wysocki, P.J., IŻycki, D., Mackiewicz, A. (2001). Improving the retroviral vector (RV) systems for immunotherapy of cancer. In: Mackiewicz, A., Kurpisz, M., Żeromski, J. (eds) Progress in Basic and Clinical Immunology. Advances in Experimental Medicine and Biology, vol 495. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-0685-0_57
Download citation
DOI: https://doi.org/10.1007/978-1-4615-0685-0_57
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-5194-8
Online ISBN: 978-1-4615-0685-0
eBook Packages: Springer Book Archive